Glenmark Pharma seeks foreign partners on biologic drugs

MUMBAI Thu Jul 10, 2014 2:58pm IST

Related Topics

Stocks

   

MUMBAI (Reuters) - Glenmark Pharmaceuticals Ltd (GLEN.NS) is in talks with foreign companies for a partnership on two of its biological drugs being tested for the treatment of chronic pain and autoimmune disorders, a senior executive said on Thursday.

Glenmark is looking for companies whose research pipelines would complement its experimental drugs, GBR830 and GBR900, which are both in phase 1, or early stage clinical trials on humans, Chairman and Managing Director Glenn Saldanha said.

He declined to give names, but said he expects to find partners by the time the two drugs complete phase 2 clinical trials, which will be "anywhere from a year to two years."

"It will depend on whether the companies are therapeutically focused on that area and whether they have a conflicting molecule in their pipeline," Saldanha said in an interview at Glenmark's headquarters in Mumbai.

While India's $15 billion pharmaceutical industry is mainly engaged in the development and sale of generic medicines, Glenmark is among the few that continue to invest in the development of original medicines. Natco Pharma Ltd (NATP.NS) and Cadila Healthcare Ltd (CADI.NS) are two other Indian companies also involved in such research.

Glenmark has as many as many as six drugs under development for treatments varying from pain and respiratory disorders to multiple sclerosis, and it is already partnered with U.S.-based Forest Laboratories Ltd FRX.N and French firm Sanofi (SASY.PA) on two of them.

Glenmark, India's sixth-largest drugmaker by sales, gets about 34 percent of its revenue from the United States, while India is its second-largest market, contributing a quarter of total revenue.

(Editing by Matt Driskill)

FILED UNDER:

Monetary Policy Committee

Reuters Showcase

Microfinance

Microfinance

Funding the unfunded: India helps small business borrow to grow  Full Article 

Insurance Sector

Insurance Sector

UK healthcare firm Bupa sees strong growth in India  Full Article 

Sensex Rises

Sensex Rises

Sensex edges up; consumer and healthcare stocks rise  Full Article 

Market Eye

Market Eye

FTSE adds nine Indian firms as large-caps in Asia-Pacific ex-Japan index   Full Article 

Indian Ocean Diplomacy

Indian Ocean Diplomacy

PM Modi to ramp up help for Indian Ocean nations to counter China influence  Full Article 

ECB Bond-Buying

ECB Bond-Buying

ECB raises growth forecasts, to start printing money next week  Full Article 

China Economy

China Economy

China signals "new normal" with lower annual growth target  Full Article 

Pharma Sector

Pharma Sector

Panel recommends waiving late-stage trials for some drugs  Full Article 

E-commerce

E-commerce

China backs e-commerce expansion in win for Alibaba, JD.com  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage